Amphista Therapeutics is a UK-based biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins.
The company’s next generation targeted protein degradation (TPD)-based medicines use a novel set of mechanisms that make use of a wider range of the body’s own innate protein degrading proteins, instead of the very narrow set of ubiquitin E3 ligase-based mechanisms used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches, providing the opportunity to treat a wider range of diseases, including cancer.
Amphista Therapeutics raised a $53 million (£38 million) Series B financing co-led by Gilde Healthcare to further develop its differentiated TPD platform and bring drug candidates to the clinic.
More Amphista Therapeutics news
Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022
Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck
Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb
Gilde Healthcare company Amphista Therapeutics appoints new chairman, Joshua T. Brumm
Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets
Levicept

Axonics Modulation Technologies

Calypso Biotech
